EASL

Early model suggests a way to predict progression-free survival

Pilot trial demonstrates that FMT can boost gut health, prevent serious infections

Phase IIb ENLIVEN trial saw success with various doses of pegozafermin

Public health expert describes pivot to provide medical aid in war-torn Ukraine

At 48 weeks, bulevirtide led to undetectable HDV RNA, normalization of ALT in up to 48%

Investigational drug more likely to resolve severe form of fatty liver disease, improve fibrosis

Noteworthy research from the European Association for the Study of the Liver annual meeting

Small fazirsiran trial sees fibrosis regressions for liver disease associated with AAT deficiency

Randomized trial showed improvements in cardiometabolic markers, but not liver fibrosis

37% higher risk observed in large German study

Nearly half of patients at week 48 had virological and biochemical response

14% of patients experienced a reinfection over the past decade

Danish study shows fibrosis screening associated with improved diet, alcohol use, and exercise

Small preliminary trial also shows hints of promising clinical results